Prestige Consumer Healthcare Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Prestige Consumer Healthcare stock.
View analyst ratings for Prestige Consumer Healthcare or view top-rated stocks.

Wall Street analysts have given Prestige Consumer Healthcare a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prestige Consumer Healthcare wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Prestige Consumer Healthcare.

Prestige Consumer Healthcare will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "5362477".

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its quarterly earnings results on Thursday, May, 6th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.01. The firm earned $237.80 million during the quarter, compared to the consensus estimate of $230.59 million. Prestige Consumer Healthcare had a trailing twelve-month return on equity of 12.65% and a net margin of 17.46%. Prestige Consumer Healthcare's quarterly revenue was down 5.3% on a year-over-year basis. During the same period last year, the company posted $0.82 earnings per share.
View Prestige Consumer Healthcare's earnings history.

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PBH shares have increased by 47.1% and is now trading at $52.81.
View which stocks have been most impacted by COVID-19.

Prestige Consumer Healthcare issued an update on its FY 2022 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of 3.580- for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.420. The company issued revenue guidance of $957 million-$962 million, compared to the consensus revenue estimate of $949.31 million.

4 equities research analysts have issued 12-month target prices for Prestige Consumer Healthcare's stock. Their forecasts range from $52.00 to $125.00. On average, they anticipate Prestige Consumer Healthcare's share price to reach $101.25 in the next year. This suggests a possible upside of 91.7% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare or view top-rated stocks among Wall Street analysts.

8 employees have rated Prestige Consumer Healthcare CEO Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among Prestige Consumer Healthcare's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Prestige Consumer Healthcare include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Medifast (MED), Nu Skin Enterprises (NUS), Inter Parfums (IPAR), USANA Health Sciences (USNA), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all of PBH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.07%), Oregon Public Employees Retirement Fund (0.04%), 6 Meridian (0.02%) and CHICAGO TRUST Co NA (0.01%). Company insiders that own Prestige Consumer Healthcare stock include Mary Beth Fritz, Paton Brett and Ronald M Lombardi.
View institutional ownership trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, and 6 Meridian.
View insider buying and selling activity for Prestige Consumer Healthcare or view top insider-selling stocks.

PBH stock was acquired by a variety of institutional investors in the last quarter, including CHICAGO TRUST Co NA, and State of Alaska Department of Revenue.
View insider buying and selling activity for Prestige Consumer Healthcare or or view top insider-buying stocks.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PBH stock can currently be purchased for approximately $52.81.

Prestige Consumer Healthcare has a market capitalization of $2.64 billion and generates $943.36 million in revenue each year. The company earns $164.68 million in net income (profit) each year or $3.24 on an earnings per share basis.

Prestige Consumer Healthcare employs 505 workers across the globe.

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Prestige Consumer Healthcare is headquartered at 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]